Least burdensome
This article was originally published in The Gray Sheet
Executive Summary
Draft guidance developed by industry/FDA task force must be reviewed by FDA's Office of Chief Counsel and Office of Policy before being released. The draft is an expansion of the task force's March 2000 "Concepts and Principles" document and includes in vitro diagnostics, according to IDE Section chief Joanne Less. Implementation of least burdensome principles can be expected to result in some inconsistencies in the Office of Device Evaluation's handling of PMAs and 510(k)s, ODE Deputy Director Phil Phillips noted. If certain companies propose a less burdensome approach, "we may accept those and there will be some apparent inconsistency in the program"
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.